Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases ; volume:8 ; number:1 ; day:18 ; month:5 ; year:2018 ; pages:1-11 ; date:12.2018
Scientific reports ; 8, Heft 1 (18.5.2018), 1-11, 12.2018
- Urheber
-
Sauzullo, Ilaria
- Beteiligte Personen und Organisationen
-
Scrivo, Rossana
Sessa, Paola
Mengoni, Fabio
Vullo, Vincenzo
Valesini, Guido
Mastroianni, Claudio Maria
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-26097-x
- URN
-
urn:nbn:de:101:1-2018071717402104043937
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sauzullo, Ilaria
- Scrivo, Rossana
- Sessa, Paola
- Mengoni, Fabio
- Vullo, Vincenzo
- Valesini, Guido
- Mastroianni, Claudio Maria
- SpringerLink (Online service)
Ähnliche Objekte (12)
Incidence of diabetic retinopathy in anti-tnf treated rheumatic disease patients with type 2 diabetes
Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases
Pulmonary thromboembolism in children with rheumatic diseases
Postnatal Care of Woman with Rheumatic Diseases
Second generation of calcium antagonists : with 63 tables
Oculocutaneous manifestations of rheumatic diseases : with 9 tables
Biosensor-based monitoring of TNF antagonists and anti-drug antibodies in inflammatory bowel disease
Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment
CNS Demyelination with TNF-α Blockers
Incidence of diabetic retinopathy in anti-tnf treated rheumatic disease patients with type 2 diabetes
Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases
Pulmonary thromboembolism in children with rheumatic diseases
Postnatal Care of Woman with Rheumatic Diseases
Second generation of calcium antagonists : with 63 tables
Oculocutaneous manifestations of rheumatic diseases : with 9 tables
Biosensor-based monitoring of TNF antagonists and anti-drug antibodies in inflammatory bowel disease
Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment
CNS Demyelination with TNF-α Blockers
Incidence of diabetic retinopathy in anti-tnf treated rheumatic disease patients with type 2 diabetes
Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases
Pulmonary thromboembolism in children with rheumatic diseases
Postnatal Care of Woman with Rheumatic Diseases
Second generation of calcium antagonists : with 63 tables
Oculocutaneous manifestations of rheumatic diseases : with 9 tables
Biosensor-based monitoring of TNF antagonists and anti-drug antibodies in inflammatory bowel disease
Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment